Strides Pharma Drug Patent Portfolio

Strides Pharma's Family Patents


Family Patents



Recently granted tentative Approvals to Strides Pharma

These tentative approvals reflect continued regulatory progress across both innovative and generic submissions related to Strides Pharma's portfolio.

Innovator tentative approvals

Drug Name Active Ingredient Submission Type Submission Category Submission Date
Stavudine; Lamivudine; Efavirenz Stavudine; Lamivudine; Efavirenz ORIG-1
Orig = Original submission
Suppl = Supplement submission
Number = submission sequence
Type 4 - New Combination 01 Jun, 2007
Stavudine; Lamivudine Stavudine; Lamivudine ORIG-1
Orig = Original submission
Suppl = Supplement submission
Number = submission sequence
Type 4 - New Combination 13 Mar, 2007
Lamivudine/zidovudine 150 Mg/300 Mg Tablets Co-packaged With Nevirapine 200 Mg Tablets Lamivudine; Zidovudine; Nevirapine ORIG-1
Orig = Original submission
Suppl = Supplement submission
Number = submission sequence
Type 4 - New Combination 02 Mar, 2007

Generic tentative approvals

Drug Name Active Ingredient Submission Type Submission Category Submission Date
Lamivudine Lamivudine SUPPL-8
Orig = Original submission
Suppl = Supplement submission
Number = submission sequence
Labeling 14 Dec, 2016
Tenofovir Disoproxil Fumarate Tenofovir Disoproxil Fumarate SUPPL-6
Orig = Original submission
Suppl = Supplement submission
Number = submission sequence
Labeling 07 Dec, 2016
Stavudine Stavudine ORIG-1
Orig = Original submission
Suppl = Supplement submission
Number = submission sequence
(Not Available) 28 Aug, 2006

Explore deeper patents analysis

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List